Pediatric Exclusivity(Pediatric Exclusivity)
A six-month extension of existing market exclusivity and patent terms granted by FDA in return for completing pediatric studies requested by the agency.
Usage Examples
- The sponsor completed the Written Request pediatric studies and received 6 months of pediatric exclusivity extending NCE exclusivity and listed patents.
- Pediatric exclusivity economics justified the $50M pediatric study investment for the blockbuster drug.
What is Pediatric Exclusivity?
Pediatric exclusivity — not to be confused with pediatric requirements under PREA or PSP — is a voluntary incentive under the Best Pharmaceuticals for Children Act (BPCA) providing six additional months of marketing exclusivity and patent term in return for completing pediatric studies specified in an FDA Written Request. The exclusivity attaches to all formulations, dosages, and indications of the drug containing the same active moiety, not just pediatric-specific uses.
The economic value of pediatric exclusivity is often substantial — six months of sales at peak revenue can exceed the cost of the pediatric studies by 10-50x for blockbuster drugs. FDA issues Written Requests based on public health value of pediatric information, not sponsor proposal. Once the sponsor submits study reports meeting the Written Request, FDA determines exclusivity qualification. The exclusivity extends both FDA-granted exclusivities (NCE, 3-year, Orphan) and associated patent terms.
Regulatory Context
This term appears most often in submission & approval workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside FDCA SECTION 505A, BPCA.
When This Matters
- The sponsor completed the Written Request pediatric studies and received 6 months of pediatric exclusivity extending NCE exclusivity and listed patents.
- Pediatric exclusivity economics justified the $50M pediatric study investment for the blockbuster drug.
Common Mistakes
- Treating submission readiness as a formatting-only check without lifecycle validation.
- Using outdated guidance references across modules and summaries.
- Missing cross-functional review between RA, CMC, and quality before submission.
Related Regulations
Frequently Asked Questions
PREA/PSP require pediatric studies as a condition of approval. Pediatric exclusivity is a voluntary incentive — FDA requests pediatric studies, sponsor voluntarily completes them, and receives 6 months of exclusivity in return. Different legal basis and incentive structure.
Yes. The 6-month extension applies to both FDA-granted exclusivities (NCE, 3-year, Orphan) AND listed Orange Book patents. This combined effect is why pediatric exclusivity is economically attractive — it extends the entire market protection period.
Only when FDA has issued a Written Request for the specific drug. FDA prioritizes Written Requests based on public health value — drugs where pediatric information would meaningfully affect treatment. Sponsors cannot request or negotiate Written Requests for arbitrary products.
Related Terms
Related Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Track ICH quality guidelines automatically and get alerts when changes impact your products
Related Regulatory Intelligence
Related Actions
Sources & References
